Patient characteristics
Characteristic . | Value . |
|---|---|
| Diagnosis, no. of patients | |
| ALL | 7 |
| AML | 4 |
| CML-BC | 1 |
| CLL | 1 |
| NHL | 2 |
| HD | 1 |
| Myeloma | 1 |
| LL | 1 |
| Median age, y (range) | 46 (12-57) |
| Sex, male/female | 12/6 |
| Median donor age, y (range) | 42 (10-62) |
| Sex-mismatched donors, no. | 6 |
| Graft source of original BMT, no. of patients | |
| Bone marrow | 13 |
| Peripheral blood stem cells | 5 |
| Conditioning regimen intensity of original BMT, no. of patients | |
| Myeloablative | 15 |
| Nonmyeloablative | 3 |
| Conditioning regimen of original BMT, no. of patients | |
| TBI based* | 12 |
| Bu/Cy | 3 |
| Flu/Cy | 3 |
| Induction chemotherapy used prior to DLI†, no. of patients | |
| Ida/AraC | 3 |
| CVAD | 3 |
| Mito/AraC | 2 |
| Flu/AraC | 2 |
| DVP, Asp | 1 |
| Ida | 1 |
| ICE | 1 |
| Mylotarg | 1 |
| Time from BMT to relapse, mo (range) | 11.5 (2-90) |
| Time from relapse to DLI, wk (range) | 6 (2-30) |
| Median DLI-unstimulated mononuclear cells, × 108 (range) | 1.5 (0.9-3.5) |
Characteristic . | Value . |
|---|---|
| Diagnosis, no. of patients | |
| ALL | 7 |
| AML | 4 |
| CML-BC | 1 |
| CLL | 1 |
| NHL | 2 |
| HD | 1 |
| Myeloma | 1 |
| LL | 1 |
| Median age, y (range) | 46 (12-57) |
| Sex, male/female | 12/6 |
| Median donor age, y (range) | 42 (10-62) |
| Sex-mismatched donors, no. | 6 |
| Graft source of original BMT, no. of patients | |
| Bone marrow | 13 |
| Peripheral blood stem cells | 5 |
| Conditioning regimen intensity of original BMT, no. of patients | |
| Myeloablative | 15 |
| Nonmyeloablative | 3 |
| Conditioning regimen of original BMT, no. of patients | |
| TBI based* | 12 |
| Bu/Cy | 3 |
| Flu/Cy | 3 |
| Induction chemotherapy used prior to DLI†, no. of patients | |
| Ida/AraC | 3 |
| CVAD | 3 |
| Mito/AraC | 2 |
| Flu/AraC | 2 |
| DVP, Asp | 1 |
| Ida | 1 |
| ICE | 1 |
| Mylotarg | 1 |
| Time from BMT to relapse, mo (range) | 11.5 (2-90) |
| Time from relapse to DLI, wk (range) | 6 (2-30) |
| Median DLI-unstimulated mononuclear cells, × 108 (range) | 1.5 (0.9-3.5) |
HD indicates Hodgkin disease; LL, lymphoblastic lymphoma; TBI, total body irradiation; Bu, busulfan; Cy, cyclophosphamide; Ida, idarubicin; AraC, cytosine arabinoside; CVAD, cyclophosphamide, vincristine, adriamycin, dexamethosone; Mito, mitoxantrone; Flu, fludarabine; DVP, daunarubicin, vincristine, prednisone; Asp, asparaginase; and ICE, ifosphamide, carboplatinum, VP16 (etoposide).
With either Cy, VP16, thiotepa/Cy, or thiotepa/Cy/VP16
For patients with AML, ALL, CML-BC, and LL; n = 14